Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 435

1.

Is radiographic progression a downside of stopping TNF-inhibitor in RA patients with low disease activity, if this is followed by flare? A sub-study of the POET-US trial.

Lamers-Karnebeek FBG, Luime JJ, Jansen TL, van Riel PLCM, Jacobs JWG.

Rheumatology (Oxford). 2019 Oct 25. pii: kez488. doi: 10.1093/rheumatology/kez488. [Epub ahead of print] No abstract available.

PMID:
31652321
2.

Predictors of biologic-free disease control in patients with rheumatoid arthritis after stopping tumor necrosis factor inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaeybroeck B, Klaasen R, van Onna M, Bernelot Moens HJ, Visser H, Schilder AM, Kok MR, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

BMC Rheumatol. 2019 Jun 13;3:3. doi: 10.1186/s41927-019-0071-x. eCollection 2019. Erratum in: BMC Rheumatol. 2019 Aug 20;3:35.

3.

Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.

Spiliopoulou A, Colombo M, Plant D, Nair N, Cui J, Coenen MJ, Ikari K, Yamanaka H, Saevarsdottir S, Padyukov L, Bridges SL Jr, Kimberly RP, Okada Y, van Riel PLC, Wolbink G, van der Horst-Bruinsma IE, de Vries N, Tak PP, Ohmura K, Canhão H, Guchelaar HJ, Huizinga TW, Criswell LA, Raychaudhuri S, Weinblatt ME, Wilson AG, Mariette X, Isaacs JD, Morgan AW, Pitzalis C, Barton A, McKeigue P.

Ann Rheum Dis. 2019 Aug;78(8):1055-1061. doi: 10.1136/annrheumdis-2018-214877. Epub 2019 Apr 29.

4.

Patient Self-Management and Tracking: A European Experience.

van Riel PLCM, Zuidema RM, Vogel C, Rongen-van Dartel SAA.

Rheum Dis Clin North Am. 2019 May;45(2):187-195. doi: 10.1016/j.rdc.2019.01.008. Review.

5.

Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.

Lamers-Karnebeek FBG, Jacobs JWG, Radstake TRDJ, van Riel PLCM, Jansen TL.

Rheumatology (Oxford). 2019 Mar 1;58(3):427-431. doi: 10.1093/rheumatology/key292.

PMID:
30383251
6.

Comparison of the construct validity and reproducibility of four different types of patient-reported outcome measures (PROMs) in patients with rheumatoid arthritis.

Renskers L, van Uden RJJC, Huis AMP, Rongen SAA, Teerenstra S, van Riel PLCM.

Clin Rheumatol. 2018 Dec;37(12):3191-3199. doi: 10.1007/s10067-018-4285-x. Epub 2018 Sep 12.

PMID:
30209696
7.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

8.

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.

Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2018 Oct;70(10):1557-1564. doi: 10.1002/art.40546. Epub 2018 Aug 23.

9.

Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis.

Bhansing KJ, VAN Rosmalen MH, VAN Engelen BG, VAN Riel PL, Pillen S, Vonk MC.

J Rheumatol. 2018 Mar;45(3):441-442. doi: 10.3899/jrheum.171188. No abstract available.

PMID:
29496919
10.

Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care.

Weijers JM, Rongen-van Dartel SAA, Hoevenaars DMGMF, Rubens M, Hulscher MEJL, van Riel PLCM.

Ann Rheum Dis. 2018 Apr;77(4):480-483. doi: 10.1136/annrheumdis-2017-212392. Epub 2017 Nov 22. Review.

PMID:
29167154
11.

Tailored Therapist-guided Internet-based Cognitive-behavioural Treatment for Psoriasis and Rheumatoid Arthritis: Two Case Reports.

Koulil SS, Ferwerda M, van Beugen S, van Middendorp H, van de Kerkhof PCM, van Riel PLCM, Evers AWM.

Acta Derm Venereol. 2018 Feb 7;98(2):225-233. doi: 10.2340/00015555-2803.

12.

Pulmonary arterial hypertension, a novelty in idiopathic inflammatory myopathies: insights and first experiences with vasoactive therapy.

Bhansing KJ, Vonk-Noordegraaf A, Oosterveer FP, van Riel PL, Vonk MC.

RMD Open. 2017 Jun 9;3(1):e000331. doi: 10.1136/rmdopen-2016-000331. eCollection 2017.

13.

Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel PLCM, Gabriel SE, Matteson EL, Kvien TK, Douglas K, Sandoo A, Arts E, Wållberg-Jonsson S, Innala L, Karpouzas G, Dessein PH, Tsang L, El-Gabalawy H, Hitchon C, Ramos VP, Yáñez IC, Sfikakis PP, Zampeli E, Gonzalez-Gay MA, Corrales A, Laar MV, Vonkeman HE, Meek I, Semb AG; A Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA).

Ann Rheum Dis. 2018 Jan;77(1):48-54. doi: 10.1136/annrheumdis-2017-211735. Epub 2017 Sep 6.

14.

Muscle ultrasonography is a potential tool for detecting fasciitis in dermatomyositis and polymyositis: comment on the article by Yoshida et al.

Bhansing KJ, van Rosmalen MH, van Engelen BG, van Riel PL, Pillen S, Vonk MC.

Arthritis Rheumatol. 2017 Nov;69(11):2248-2249. doi: 10.1002/art.40240. No abstract available.

15.

Development of an item bank to measure factual disease and treatment related knowledge of rheumatoid arthritis patients in the treat to target era.

de Jonge MJ, Oude Voshaar MAH, Huis AMP, van de Laar MAFJ, Hulscher MEJL, van Riel PLCM.

Patient Educ Couns. 2018 Jan;101(1):67-73. doi: 10.1016/j.pec.2017.07.019. Epub 2017 Jul 21.

PMID:
28811047
16.

Impact of Stopping Tumor Necrosis Factor Inhibitors on Rheumatoid Arthritis Patients' Burden of Disease.

Ghiti Moghadam M, Ten Klooster PM, Vonkeman HE, Kneepkens EL, Klaasen R, Stolk JN, Tchetverikov I, Vreugdenhil SA, van Woerkom JM, Goekoop-Ruiterman YPM, Landewé RBM, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):516-524. doi: 10.1002/acr.23315.

17.

Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study.

Arts EE, Fransen J, Den Broeder AA, van Riel PLCM, Popa CD.

Ann Rheum Dis. 2017 Oct;76(10):1693-1699. doi: 10.1136/annrheumdis-2016-210997. Epub 2017 Jun 12.

PMID:
28606965
18.

Limited value for ultrasonography in predicting flare in rheumatoid arthritis patients with low disease activity stopping TNF inhibitors.

Lamers-Karnebeek FB, Luime JJ, Ten Cate DF, Teerenstra S, Swen NWAA, Gerards AH, Hendrikx J, van Rooyen EM, Voorneman R, Haagsma C, Basoski N, de Jager M, Ghiti Moghadam M, Efde MN, Goekoop-Ruiterman YPM, van Riel PLCM, Jacobs JWG, Jansen TL.

Rheumatology (Oxford). 2017 Sep 1;56(9):1560-1565. doi: 10.1093/rheumatology/kex184.

PMID:
28595367
19.

Correction: Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Kitas GD, van Riel PL, Gabriel SE, Semb AG; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA).

PLoS One. 2017 Apr 7;12(4):e0175605. doi: 10.1371/journal.pone.0175605. eCollection 2017.

20.

Rheumatoid arthritis-specific cardiovascular risk scores are not superior to general risk scores: a validation analysis of patients from seven countries.

Crowson CS, Gabriel SE, Semb AG, van Riel PLCM, Karpouzas G, Dessein PH, Hitchon C, Pascual-Ramos V, Kitas GD; Trans-Atlantic Cardiovascular Consortium for Rheumatoid Arthritis.

Rheumatology (Oxford). 2017 Jul 1;56(7):1102-1110. doi: 10.1093/rheumatology/kex038.

21.

Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis.

Crowson CS, Rollefstad S, Kitas GD, van Riel PL, Gabriel SE, Semb AG; A Trans-Atlantic Cardiovascular Risk Consortium for Rheumatoid Arthritis (ATACC-RA).

PLoS One. 2017 Mar 23;12(3):e0174656. doi: 10.1371/journal.pone.0174656. eCollection 2017. Erratum in: PLoS One. 2017 Apr 7;12 (4):e0175605.

22.

IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis.

Damen MS, Agca R, Holewijn S, de Graaf J, Dos Santos JC, van Riel PL, Fransen J, Coenen MJ, Nurmohamed MT, Netea MG, Dinarello CA, Joosten LA, Heinhuis B, Popa CD.

Sci Rep. 2017 Jan 30;7:41629. doi: 10.1038/srep41629.

23.

A different perspective: Inflammatory rheumatic diseases and other organs.

Kitas GD, van Riel PL.

Best Pract Res Clin Rheumatol. 2016 Oct;30(5):787-788. doi: 10.1016/j.berh.2016.10.014. Epub 2016 Nov 22. No abstract available.

PMID:
27964788
24.

The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis.

van Riel PL, Renskers L.

Clin Exp Rheumatol. 2016 Sep-Oct;34(5 Suppl 101):S40-S44. Epub 2016 Oct 18. Review.

25.

Systematic review of patient-reported outcome measures (PROMs) for assessing disease activity in rheumatoid arthritis.

Hendrikx J, de Jonge MJ, Fransen J, Kievit W, van Riel PL.

RMD Open. 2016 Aug 18;2(2):e000202. doi: 10.1136/rmdopen-2015-000202. eCollection 2016.

26.

Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It.

Bhansing KJ, van Riel PL, van Engelen BG, Fransen J, Vonk MC.

J Rheumatol. 2016 Oct;43(10):1838-1843. Epub 2016 Aug 15.

PMID:
27528573
27.

Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.

Manders SH, Kievit W, Jansen TL, Stolk JN, Visser H, Schilder AM, Vonkeman HE, Adang E, van de Laar MA, van Riel PL.

J Rheumatol. 2016 Oct;43(10):1787-1794. Epub 2016 Aug 1.

PMID:
27481900
28.

Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF.

Arthritis Res Ther. 2016 Jun 20;18(1):144. No abstract available.

29.

Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis.

Kievit W, Maurits JS, Arts EE, van Riel PL, Fransen J, Popa CD.

Arthritis Care Res (Hoboken). 2017 Feb;69(2):175-182. doi: 10.1002/acr.22929.

30.

A multidimensional 'path analysis' model of factors explaining fatigue in rheumatoid arthritis.

Rongen-van Dartel SA, Repping-Wuts H, Donders R, van Hoogmoed D, Knoop H, Bleijenberg G, van Riel PL, Fransen J.

Clin Exp Rheumatol. 2016 Mar-Apr;34(2):200-6. Epub 2016 Mar 25.

PMID:
27049923
31.

The influence of patient perceptions of disease on medication intensification in daily practice.

Hendrikx J, Kievit W, Fransen J, van Riel PL.

Rheumatology (Oxford). 2016 Nov;55(11):1938-1945. Epub 2016 Mar 23.

PMID:
27009827
32.

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration.

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, Ancuta I, Pavelka K, Nordström DC, Gabay C, Canhão H, Tomsic M, van Riel PL, Gomez-Reino J, Kvien TK, van Vollenhoven RF; Rheumatic Diseases Portuguese Register.

Arthritis Res Ther. 2016 Feb 16;18:50. doi: 10.1186/s13075-016-0951-z. Erratum in: Arthritis Res Ther. 2016;18(1):144.

33.

Stopping Tumor Necrosis Factor Inhibitor Treatment in Patients With Established Rheumatoid Arthritis in Remission or With Stable Low Disease Activity: A Pragmatic Multicenter, Open-Label Randomized Controlled Trial.

Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, Landewé R, Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration.

Arthritis Rheumatol. 2016 Aug;68(8):1810-7. doi: 10.1002/art.39626.

34.

Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.

Steunebrink LM, Vonkeman HE, ten Klooster PM, Hoekstra M, van Riel PL, van de Laar MA.

Clin Rheumatol. 2016 Mar;35(3):609-15. doi: 10.1007/s10067-016-3191-3. Epub 2016 Feb 6.

35.

Monitoring rheumatoid arthritis using an algorithm based on patient-reported outcome measures: a first step towards personalised healthcare.

Hendrikx J, Fransen J, van Riel PL.

RMD Open. 2015 Nov 19;1(1):e000114. doi: 10.1136/rmdopen-2015-000114. eCollection 2015.

36.

Impaired Porphyromonas gingivalis-Induced Tumor Necrosis Factor Production by Dendritic Cells Typifies Patients With Rheumatoid Arthritis.

Santegoets KC, Wenink MH, Braga FA, Cossu M, Lamers-Karnebeek FB, van Riel PL, Sturm PD, van den Berg WB, Radstake TR.

Arthritis Rheumatol. 2016 Apr;68(4):795-804. doi: 10.1002/art.39514.

37.

Tapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registry.

Manders SH, van de Laar MA, Rongen-van Dartel SA, Bos R, Visser H, Brus HL, Jansen T, Vonkeman HE, van Riel PL, Kievit W.

RMD Open. 2015 Oct 8;1(1):e000147. doi: 10.1136/rmdopen-2015-000147. eCollection 2015.

38.

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.

Gabay C, Riek M, Hetland ML, Hauge EM, Pavelka K, Tomšič M, Canhao H, Chatzidionysiou K, Lukina G, Nordström DC, Lie E, Ancuta I, Hernández MV, van Riel PL, van Vollenhoven R, Kvien TK.

Ann Rheum Dis. 2016 Jul;75(7):1336-42. doi: 10.1136/annrheumdis-2015-207760. Epub 2015 Sep 15.

39.

Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures.

Oude Voshaar MA, Ten Klooster PM, Glas CA, Vonkeman HE, Taal E, Krishnan E, Bernelot Moens HJ, Boers M, Terwee CB, van Riel PL, van de Laar MA.

Rheumatology (Oxford). 2015 Dec;54(12):2221-9. doi: 10.1093/rheumatology/kev265. Epub 2015 Jul 29.

PMID:
26224306
40.

Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.

Manders SH, Kievit W, Adang E, Brus HL, Moens HJ, Hartkamp A, Hendriks L, Brouwer E, Visser H, Vonkeman HE, Hendrikx J, Jansen TL, Westhovens R, van de Laar MA, van Riel PL.

Arthritis Res Ther. 2015 May 22;17:134. doi: 10.1186/s13075-015-0630-5.

41.

The detection of monosodium urate crystals in synovial fluid after long-term and varying storage conditions.

Kienhorst LB, Janssens HJ, Eijgelaar RS, Radstake TR, van Riel PL, Janssen M.

Joint Bone Spine. 2015 Dec;82(6):470-1. doi: 10.1016/j.jbspin.2014.10.020. Epub 2015 Apr 24. No abstract available.

PMID:
25921802
42.

Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms.

Arts EE, Popa CD, Den Broeder AA, Donders R, Sandoo A, Toms T, Rollefstad S, Ikdahl E, Semb AG, Kitas GD, Van Riel PL, Fransen J.

Ann Rheum Dis. 2016 Apr;75(4):674-80. doi: 10.1136/annrheumdis-2014-206879. Epub 2015 Feb 17.

PMID:
25691119
43.

Increased fascial thickness of the deltoid muscle in dermatomyositis and polymyositis: An ultrasound study.

Bhansing KJ, Van Rosmalen MH, Van Engelen BG, Vonk MC, Van Riel PL, Pillen S.

Muscle Nerve. 2015 Oct;52(4):534-9. doi: 10.1002/mus.24595. Epub 2015 Aug 20.

PMID:
25655014
44.

Effect of Aerobic Exercise Training on Fatigue in Rheumatoid Arthritis: A Meta-Analysis.

Rongen-van Dartel SA, Repping-Wuts H, Flendrie M, Bleijenberg G, Metsios GS, van den Hout WB, van den Ende CH, Neuberger G, Reid A, van Riel PL, Fransen J.

Arthritis Care Res (Hoboken). 2015 Aug;67(8):1054-62. doi: 10.1002/acr.22561.

45.

Personalizing treatment targets in rheumatoid arthritis by using a simple prediction model.

de Punder YM, Jansen TL, van Ede AE, den Broeder AA, van Riel PL, Fransen J.

J Rheumatol. 2015 Mar;42(3):398-404. doi: 10.3899/jrheum.140085. Epub 2015 Jan 15.

PMID:
25593241
46.

A simplified baseline prediction model for joint damage progression in rheumatoid arthritis: a step toward personalized medicine.

de Punder YM, van Riel PL, Fransen J.

J Rheumatol. 2015 Mar;42(3):391-7. doi: 10.3899/jrheum.140327. Epub 2015 Jan 15.

PMID:
25593237
47.

Assessment of fatigue in rheumatoid arthritis: a psychometric comparison of single-item, multiitem, and multidimensional measures.

Oude Voshaar MA, Ten Klooster PM, Bode C, Vonkeman HE, Glas CA, Jansen T, van Albada-Kuipers I, van Riel PL, van de Laar MA.

J Rheumatol. 2015 Mar;42(3):413-20. doi: 10.3899/jrheum.140389. Epub 2015 Jan 15.

PMID:
25593225
48.

Initial combination therapy versus step-up therapy in treatment to the target of remission in daily clinical practice in early rheumatoid arthritis patients: results from the DREAM registry.

Steunebrink LM, Versteeg GA, Vonkeman HE, Ten Klooster PM, Kuper HH, Zijlstra TR, van Riel PL, van de Laar MA.

Arthritis Res Ther. 2016 Mar 8;18:60. doi: 10.1186/s13075-016-0962-9.

49.

Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice.

Manders SH, Kievit W, Adang E, Jansen TJ, Stolk JN, Visser H, Schilder AM, Vonkeman HE, van de Laar MA, van Riel PL.

Ann Rheum Dis. 2015 Mar;74(3):e24. doi: 10.1136/annrheumdis-2014-207005. Epub 2014 Dec 5. No abstract available.

PMID:
25480886
50.

The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers.

Kearsley-Fleet L, Závada J, Hetland ML, Nordström DC, Aaltonen KJ, Listing J, Zink A, Gati T, Rojkovich B, Iannone F, Gremese E, van Riel PLCM, van de Laar MAFJ, Lie E, Kvien TK, Canhão H, Fonseca JE, Rotar Ž, Loza E, Carmona L, Askling J, Johansson K, Finckh A, Dixon WG, Hyrich KL.

Rheumatology (Oxford). 2015 Jun;54(6):1074-1079. doi: 10.1093/rheumatology/keu446. Epub 2014 Nov 27.

PMID:
25433042

Supplemental Content

Loading ...
Support Center